Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 8
2004 6
2005 7
2006 10
2007 10
2008 6
2009 9
2010 9
2011 14
2012 9
2013 7
2014 5
2015 7
2016 2
2017 1
2018 3
2019 2
2020 4
2021 2
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.
Yamato M, Hasegawa J, Maejima T, Hattori C, Kumagai K, Watanabe A, Nishiya Y, Shibutani T, Aida T, Hayakawa I, Nakada T, Abe Y, Agatsuma T. Yamato M, et al. Among authors: hasegawa j. Mol Cancer Ther. 2022 Apr 1;21(4):635-646. doi: 10.1158/1535-7163.MCT-21-0554. Mol Cancer Ther. 2022. PMID: 35149548 Free PMC article.
Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy.
Ichimura Y, Waguri S, Sou YS, Kageyama S, Hasegawa J, Ishimura R, Saito T, Yang Y, Kouno T, Fukutomi T, Hoshii T, Hirao A, Takagi K, Mizushima T, Motohashi H, Lee MS, Yoshimori T, Tanaka K, Yamamoto M, Komatsu M. Ichimura Y, et al. Among authors: hasegawa j. Mol Cell. 2013 Sep 12;51(5):618-31. doi: 10.1016/j.molcel.2013.08.003. Epub 2013 Sep 5. Mol Cell. 2013. PMID: 24011591 Free article.
Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate.
Iida K, Abdelhamid Ahmed AH, Nagatsuma AK, Shibutani T, Yasuda S, Kitamura M, Hattori C, Abe M, Hasegawa J, Iguchi T, Karibe T, Nakada T, Inaki K, Kamei R, Abe Y, Nomura T, Andersen JL, Santagata S, Hemming ML, George S, Doi T, Ochiai A, Demetri GD, Agatsuma T. Iida K, et al. Among authors: hasegawa j. Cancer Discov. 2021 Jun;11(6):1508-1523. doi: 10.1158/2159-8290.CD-20-1434. Epub 2021 Feb 12. Cancer Discov. 2021. PMID: 33579785 Clinical Trial.
Natural killer cell biology: an update and future directions.
Campbell KS, Hasegawa J. Campbell KS, et al. Among authors: hasegawa j. J Allergy Clin Immunol. 2013 Sep;132(3):536-544. doi: 10.1016/j.jaci.2013.07.006. Epub 2013 Jul 30. J Allergy Clin Immunol. 2013. PMID: 23906377 Free PMC article. Review.
Novel anti-EPHA2 antibody, DS-8895a for cancer treatment.
Hasegawa J, Sue M, Yamato M, Ichikawa J, Ishida S, Shibutani T, Kitamura M, Wada T, Agatsuma T. Hasegawa J, et al. Cancer Biol Ther. 2016 Nov;17(11):1158-1167. doi: 10.1080/15384047.2016.1235663. Epub 2016 Sep 21. Cancer Biol Ther. 2016. PMID: 27653549 Free PMC article.
Efficacy and safety of twice-daily tramadol hydrochloride bilayer sustained-release tablets with an immediate release component for postherpetic neuralgia: Results of a Phase III, randomized, double-blind, placebo-controlled, treatment-withdrawal study.
Kawai S, Hasegawa J, Ito H, Fukuuchi Y, Nakano H, Ohtani H, Sasaki K, Adachi T. Kawai S, et al. Among authors: hasegawa j. Pain Pract. 2023 Mar;23(3):277-289. doi: 10.1111/papr.13190. Epub 2022 Dec 25. Pain Pract. 2023. PMID: 36478501 Clinical Trial.
113 results